Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body...
Event to be Held January 19, 2021 at 8:00 am ET; Will Feature Prominent Otolaryngology and Audiology Key Opinion Leaders Phase 2a Day-90 Readout for FX-322, Frequency’s Lead Product Candidate, for Acquired Sensorineural Hearing Loss Anticipated in Late Q1 2021; End ...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chi...
Frequency Therapeutics (FREQ): Q3 GAAP EPS of -$0.16 beats by $0.16.Revenue of $11.25M (-53.6% Y/Y) beats by $5.37M.Cash, cash equivalents and short-term investments of $224.2M.Press Release For further details see: Frequency Therapeutics EPS beats by $0.16, beats on revenue
Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the body, so if successful, Frequency's technology should be broadly extendable into other areas...
Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter Frequency Therapeutics, ...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Di...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of ...
Company Overview Frequency Therapeutics ( FREQ ) is a clinical-stage company targeting sensorineural hearing loss ((SNHL)). SNHL, currently, affects more than 40M people in the US and that number is expected to grow by 20% over the next decade, representing a substantial domestic market. The...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...